Highly variable NTID [Regulatives / Guidelines]

posted by d_labes  – Berlin, Germany, 2015-09-23 10:23 (3515 d 21:06 ago) – Posting: # 15454
Views: 17,510

Dear Helmut,

❝ ❝ I had interpreted the sentence "Dabigatran demonstrated a steep exposure response relationship for both efficacy and safety." as some sort of NTID.


❝ Me too. Seems that the innovator (Boehringer Ingelheim) assessed the variabilities in its studies.

❝ This is the first example I’m aware of were the observation “HVDs/HVDPs are safe drugs since they have a flat dose/response-curve” seemingly does not hold.


Oh I see. That's the reason for the sentence "Therefore applicants should not use the reference-scaled average bioequivalence (BE) approach to widen the BE limits for dabigatran BE evaluation" in the dabigatran guidance.

Seems it's time for a new term: HVNTID :cool:

❝ A dirty story? Wikipedia ...


A really dirty story :vomit:. So much to "To cheat is Indian" (My exculpation to the Indian members of this forum).

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
123 visitors (0 registered, 123 guests [including 7 identified bots]).
Forum time: 07:30 CEST (Europe/Vienna)

Freedom is always and exclusively
freedom for the one
who thinks differently.    Rosa Luxemburg

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5